HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: Implications for immune escape in vivo

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 6, 2005, Pages 523-528

  Wischhusen, Jörg ^a,b   Friese, Manuel A ^a,c   Mittelbronn, Michel ^b   Meyermann, Richard ^b   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti tumor immunity; CD94 NKG2A; Glioma; HLA E; NK cells; NKG2D

Indexed keywords

CD94 ANTIGEN; HLA E ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; SMALL INTERFERING RNA;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR IMMUNITY;

EID: 20344402306     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/64.6.523     Document Type: Article

References (23)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60
2. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995;21:128-51
3. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-29
4. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003;63:8996-9006
5. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-β; enhances NKG2D-mediatedantiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004;64:7596-603
6. Lanier LL. NK cell receptors. Annu Rev Immunol 1998;16:359-93
7. Gunturi A, Berg RE, Forman J. The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res 2004;30:29-34
8. Braud VM, Allan DS, O'Callaghan CA. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-99
9. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2 A. Proc Natl Acad Sci USA 1998;95:5199-204
10. Vales-Gomez M, Reybum HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. Embo J 1999;18:4250-60
11. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 1997;27:1164-69
12. Bertone S, Schiavetti F, Bellomo R, et al. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 1999;29:23-29
13. Ishitani A, Sageshima N, Lee N, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E. F, and G in materaal-placental immune recognition. J Immunol 2003;171:1376-84
14. Ulbrecht M, Honka T, Person S, Johnson JP, Weiss EH. The HLA-E gene encodes two differentially regulated transcripts and a cell surface protein. J Immunol 1992;149:2945-53
15. Hu D, Tkizawa K, Lu L, et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004;5:516-23
16. Marin R, Ruiz-Cabello F, Pedrinaci S, et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003;54:767-75
17. Malmberg KJ, Levitsky V, Norell H, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 2002;110:1515-23
18. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003;22:8233-45
19. Valiante NM, Rengaraju M, Trinchieri G. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 1992;145:187-98
20. Robertson MJ, Cochran KJ, Cameron C, et al. Characterization of a cell line. NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406-15
21. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-98
22. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: An alternative strategy of immune escape. J Immunol 2002;168:4772-80
23. Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003;100:4120-25